Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human dose-escalation and expansion study of GEN1044 in advanced malignant solid tumors
MOH_2020-07-26_008713Phase 2Active, not recruiting
- Sponsor
- Genmab
- Start
- Jun 2020
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of GEN1044 in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC) and 5 more, sponsored by Genmab. Primary endpoints: Recommended phase 2 dose, Safety profile and 1 more. Started Jun 2020; status: active, not recruiting.
02
Drugs
GEN1044
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)endometrial cancer (EC)prostate cancer (PCa)
Beyond the preview
Go deeper on MOH_2020-07-26_008713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-07-26_008713.